These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27248434)

  • 21. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.
    Lau JK; Zhang X; Yu J
    J Pathol; 2017 Jan; 241(1):36-44. PubMed ID: 27757953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
    Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
    Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STK25 is a critical determinant in nonalcoholic steatohepatitis.
    Amrutkar M; Chursa U; Kern M; Nuñez-Durán E; Ståhlman M; Sütt S; Borén J; Johansson BR; Marschall HU; Blüher M; Mahlapuu M
    FASEB J; 2016 Oct; 30(10):3628-3643. PubMed ID: 27421788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.
    Jump DB; Lytle KA; Depner CM; Tripathy S
    Pharmacol Ther; 2018 Jan; 181():108-125. PubMed ID: 28723414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically modified mouse models for the study of nonalcoholic fatty liver disease.
    Nagarajan P; Mahesh Kumar MJ; Venkatesan R; Majundar SS; Juyal RC
    World J Gastroenterol; 2012 Mar; 18(11):1141-53. PubMed ID: 22468076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
    Machado MV; Kruger L; Jewell ML; Michelotti GA; Pereira Tde A; Xie G; Moylan CA; Diehl AM
    Dig Dis Sci; 2016 Jan; 61(1):137-48. PubMed ID: 26403427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Which animal models of nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) have more practical value in experimental investigations?].
    Duan NN; Wu J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):230-3. PubMed ID: 27095770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging.
    Koch LK; Yeh MM
    Ann Diagn Pathol; 2018 Dec; 37():83-90. PubMed ID: 30312882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer.
    Lau JKC; Zhang X; Yu J
    Adv Exp Med Biol; 2018; 1061():139-147. PubMed ID: 29956212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH.
    Takeuchi M; Sakasai-Sakai A; Takata T; Ueda T; Takino J; Tsutsumi M; Hyogo H; Yamagishi S
    Med Hypotheses; 2015 May; 84(5):490-3. PubMed ID: 25697114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides.
    Kořínková L; Pražienková V; Černá L; Karnošová A; Železná B; Kuneš J; Maletínská L
    Front Endocrinol (Lausanne); 2020; 11():597583. PubMed ID: 33324348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How effective are nonalcoholic fatty liver disease models for drug discovery?
    Hundertmark J; Tacke F
    Expert Opin Drug Discov; 2020 Nov; 15(11):1237-1240. PubMed ID: 32524859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.